作者
Thomas D. Penning,Nizal S. Chandrakumar,Barbara B. Chen,Helen Y. Chen,B. N. Desai,Stevan W. Djurić,Stephen H. Docter,Alan F. Gasiecki,Richard A. Haack,Julie M. Miyashiro,Mark A. Russell,Stella S. Yu,David G. Corley,Richard C. Durley,Brian F. Kilpatrick,Barry L. Parnas,Leslie J. Askonas,James K. Gierse,Elizabeth I. Harding,Maureen Highkin,James F. Kachur,Suzanne H. Kim,Gwen G. Krivi,Doreen Villani-Price,E.Yvonne Pyla,Walter G. Smith,Nayereh Ghoreishi‐Haack
摘要
Leukotriene B(4) (LTB(4)) is a pro-inflammatory mediator that has been implicated in the pathogenesis of a number of diseases including inflammatory bowel disease (IBD) and psoriasis. Since the action of LTA(4) hydrolase is the rate-limiting step for LTB(4) production, this enzyme represents an attractive pharmacological target for the suppression of LTB(4) production. From an in-house screening program, SC-22716 (1, 1-[2-(4-phenylphenoxy)ethyl]pyrrolidine) was identified as a potent inhibitor of LTA(4) hydrolase. Structure-activity relationship (SAR) studies around this structural class resulted in the identification of a number of novel, potent inhibitors of LTA(4) hydrolase, several of which demonstrated good oral activity in a mouse ex vivo whole blood assay.